Viking Therapeutics remains a clinical-stage specialist developing novel metabolic and endocrine disorder therapies, with VK2735—their dual GLP-1/GIP agonist—advancing through Phase 3 subcutaneous trials. Their oral formulation also demonstrated positive Phase 2b results, positioning them strategically in obesity treatment beyond the dominant GLP-1 market. However, ongoing licensing disputes with Ligand Pharmaceuticals pose substantial risks to their pipeline’s integrity. The company’s financial health, underpinned by approximately $126 million in cash and a strong current ratio of 4.72, supports sustained R&D investments as Viking targets regulatory milestones amid intense competition from large pharmaceutical incumbents.